Kyoko Nakagawa-Goto, PhD

Kyoko Nakagawa-Goto, PhD
  • Research Associate Professor
Contact Info

Chemical Biology and Medicinal Chemistry

Eshelman School of Pharmacy

goto@email.unc.edu

Work: (919) 883-4263

313 Beard Hall
Campus Box 7568
Chapel Hill NC 27599

vCard
 
You are here: Home › Directory › Kyoko Nakagawa-Goto, PhD

Kyoko Nakagawa-Goto, PhD

RESEARCH SYNOPSIS

Discovery and development of drug candidates through total syntheses and synthetic modifications of bioactive natural products focused on antitumor and anti-HIV agents.

PROFILE

Kyoko Nakagawa-Goto received her PhD in Pharmaceutical Science with an emphasis in chemistry from the Graduate School of Natural Science & Technology at Kanazawa University in Japan. She worked as an Assistant Professor in the same university until 1998. She received a Japanese Ministry of Education Fellowship in 1996 as well as Uehara Memorial Foundation International Research Fellowship in 1998. These fellowships allowed her to join the Department of Chemistry at University of California at Berkeley and Department of Chemistry at University of North Carolina at Chapel Hill (UNC-CH) as a visiting scientist. She moved into our school to involve in Medicinal Chemistry in 2002 and is currently appointed as a Research Associate Professor. She has published more than 50 articles in the field of organic and medicinal chemistry.

RESEARCH INTERESTS

A) Total syntheses of bioactive natural products such as flavonoids, terpenoids, macrolide lactones and alkaloids.

The limited availability of a natural source often impedes the further biological evaluation of bioactive natural products. Synthetic studies can provide dependable amounts of the bioactive compound, as well as readily provide new modified preclinical drug candidates. (To see more detail, Click here)

B) Design, synthesis and structure-activity relationship of bioactive natural products.

Because chemical modification of lead compounds can enhance desired biological activities, improve bioavailability, or reduce adverse actions, this process has produced numerous effective drug candidates in clinical use or trials. Structure-activity relationship (SAR) studies using chemical modification are also important to establish the essential pharmacophore(s) of a drug candidate. They determine the structural features of a compound class that are essential for and important to biological activity. (To see more detail, Click here)

C) Mechanisms of action study for promising antitumor agents by collaboration and discussion with biologists.

Determination of the cellular target of bioactive agent contributes significantly to the mechanism of action and SAR studies at the molecular level. We design and synthesize photoaffinity- or biotin-labeled bioactive agents to identify the cellular target.

 

TEN MOST RECENT PUBLICATIONS

(* Corresponding Author)

  1. Y. Asada, A. Sukemori,T. Watanabe, K. J. Malla, T. Yoshikawa,W. Li, K. Koike, C.H. Chen, T. Akiyama, K. Qian, K. Nakagawa-Goto, S.L. Morris-Natschke, and K. H. Lee, Stelleralides A-C, Novel Potent Anti-HIV Daphnane-Type Diterprnoids from Stellera Chamaejaseme, Org. Lett., 2011, 13, 2904-2907. [PMID: 21561135]
  2. T.C. Kuo, P. C. Chiang, C. C. Yu, K. Nakagawa-Goto, K.F. Bastow, K.H. Lee, and J. H. Guh, A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways, Biochem. Pharm. 2011, 81, 1136-1144. [PMID: 21371443]
  3. Y. Dong, K. Nakagawa-Goto, C.Y. Lai,S.L. Morris-Natschke,K. F. Bastow,and K. H. Lee,Antitumor agents 287. Substituted 4-Amino-2H-pyran -2-one Analogs (APO) Reveal a New Scaffold from Neo-tanshinlactone with In Vitro Anticancer Activity,  Bioorg. Med. Chem. Lett. 2011, 21, 2341-2344. [PMID:21420855]
  4. K. Nakagawa-Goto,* and M. T. Crimmins, Synthetic Approaches to the Bottom Half Fragment for Bryostatin 11, Synlett 2011, 11, 1555-1558.
  5. K. Nakagawa-Goto,* and M. T. Crimmins, Formal Synthesis of the Bryostatin Northern Hemisphere: Asymmetric Synthesis of the B-ring and C(1)-C(9) Fragment, Synlett. 2011, 10, 1413-1418.
  6. K. Nakagawa-Goto,* and M. T. Crimmins, Toward the Total Synthesis of Bryostatin 11: Stereoselective Construction of the C13-Exocyclic Enoate in the C1-C16 Fragment, Synth. Commun. 2011, 41, 3032-3038.
  7. K. Nakagawa-Goto,* P. C. Wu,K. F. Bastow,H.Y. Chen,J.C.Lin,H.Wen,J. Yang,M. Goto, S. L. Morris-Natschke,P.C. Yang, and K. H. Lee Antitumor Agents 283. Synthesis and Biological Evaluation of Desmosdumotin C Analogs as Potent Antitumor Agents, Bioorg. Med. Chem. 2011, 19, 1816-1822. [PMID:21296579]
  8. K. Nakagawa-Goto,* P. C.Wu,C.Y. Lai, E. Hamel,H. Zhu, L. Zhang, T. Kozaka, E. Ohkoshi, M. Goto, K. F. Bastow, and K. H. Lee, Antitumor Agents 284. A New Desmosdumotin B Analogue with Bicyclic B-ring as Cytotoxic and Antitubulin Agent, J. Med. Chem. 2011, 54, 1244-1255. [PMID:21284385]
  9. Y. Dong, K. Nakagawa-Goto, C.Y. Lai,S.L. Morris-Natschke,K. F. Bastow,and K. H. Lee,Antitumor agents 281. Design, Synthesis, and Biological Activity of Substituted 4-Amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one Analogs (ATBO) as In Vitro Anticancer Agents,  Bioorg. Med. Chem. Lett. 2011, 21, 546-549. [PMID:21087859]
  10. Y. Dong, K. Nakagawa-Goto, C.Y. Lai,Y. Kim, S.L. Morris-Natschke,E. Y.-H. P. Lee, K. F. Bastow,and K. H. Lee,Antitumor agents 279. Structure-Activity Relationship and In Vivo Studies of Novel 2-(Furan-2-yl)naphthalen-1-ol (FNO) Analgos as Potent and Selective Anti-Breast Cancer Agents, Bioorg. Med. Chem. Lett. 2011, 21, 52-57. [PMID:21147529]

Document Actions